• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 288

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class...

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

Dreamshadow Transpersonal Breathwork

Statement Regarding The Church of the Sacred Synthesis

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

The Role of Oxytocin in MDMA’s Prosocial Effects

The Ancestral Healing Power of Ayahuasca

Pharmacological Testing in Psychedelic Research

Catching Up with the Psychedelic Entourage Effect: Part 4 – CaaMTech

Ayahuasca’s Role in the Entourage Effect and Depression

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

1...287288289Page 288 of 289

EDITOR PICKS

Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer...

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

Dreamshadow Transpersonal Breathwork

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©